Blood-protein set distinguishes malignant and benign lung tumors

Share this article:

A combination of blood proteins was able to differentiate between benign lung nodules and early-stage lung cancer with 90% probability, thereby providing a diagnostic tool to avoid invasive biopsy on benign nodules.

Only an estimated 20% of patients with lung nodules who undergo biopsy or surgery actually have a cancerous nodule, as noted in a statement from Science Translational Medicine, in which the study was published (2013;5[207]:207ra142).

Paul Kearney, PhD, and fellow investigators established the group of 13 blood-based proteins, known as a classifier, after identifying and creating a multiple reaction monitoring (MRM) assay for 371 protein candidates. Kearney is the president and chief science officer of Indi (Integrated Diagnostics), the molecular diagnostics company in Seattle, Washington, whose researchers helped develop the classifier by collecting plasma samples from 143 persons across three study sites. All of the samples came from persons with benign or stage 1A lung cancer.

To evaluate the diagnostic value of various combinations of biomarkers, the investigative team applied the MRM assays to the plasma samples. The 13-protein classifier that emerged was validated on an independent set of 104 plasma samples, exhibiting a negative predictive value (NPV) of 90%. Validation performance on samples from a fourth clinical site showed an NPV of 94%, which was indicative of the general effectiveness of the classifier.

The classifier score was independent of patient nodule size, smoking history, and age, all of which are risk factors used for clinical management of pulmonary nodules. These findings led Kearney and colleagues to conclude that this molecular test provides a potential complementary tool to help clinicians in lung cancer diagnosis.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

New drug shows promise in early studies for metastatic breast cancer

The new oral drug LY2835219, an inhibitor of cyclin-dependent kinases 4 and 6, showed early promise as monotherapy for patients with metastatic breast cancer.

Early promise against melanoma from new antibody-drug conjugate

The investigational drug DEDN6525A, a new antibody-drug conjugate, was safe, tolerable, and showed hints of activity against three forms of melanoma: cutaneous, mucosal, and ocular.

Aging is sped up in breast cancer survivors who underwent adjuvant chemotherapy

Adjuvant chemotherapy for breast cancer is gerontogenic, defined as accelerating the pace of physiologic aging, a new study reported.